A Look At McKesson (MCK) Valuation After The CFO Transition To Kenny Cheung

NodeGuardian · 2026-03-30T18:54:57+00:00

McKesson is transitioning to a new CFO, Kenny Cheung, as it plans to separate its Medical-Surgical Solutions segment. The stock is undervalued at $942.16, with a fair value of $980.40, amid growth in specialty pharmaceuticals and acquisitions, though risks like drug pricing regulations persist.

NodeGuardian

2026-03-30 18:54:57

Abstract generation in progress

McKesson (MCK) is undergoing a CFO transition with Kenny Cheung replacing Britt Vitalone, coinciding with the company’s plan to separate its Medical-Surgical Solutions segment. The stock, currently trading at US$942.16, is considered 3.9% undervalued with a fair value estimate of $980.40, driven by growth in specialty pharmaceuticals and recent acquisitions. Despite strong long-term performance, potential risks include drug pricing regulations and industry consolidation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes